Oncos Therapeutics initiates Phase I clinical study of CGTG-102, an oncolytic adenovirus for the treatment of solid tumor cancers
May 29, 2012. Helsinki, Finland – Oncos Therapeutics today announced the successful initiation of its Phase I clinical study of CGTG-102, an oncolytic adenovirus suggested as a potential new treatment for many types of solid tumors. The first patients have already completed the safety assessment part of the study.
“We are proud to be the first clinic in Northern Europe to start a clinical study with oncolytic viruses“, comments the Principal Investigator of the study, Chief Physician of Docrates Hospital, Dr. Timo Joensuu. “We believe that oncolytic adenoviruses, a generally well tolerated therapy, will have an important role in the future of cancer treatments.“
“In our earlier experimental use the treatment has appeared to be safe for cancer patients. We really look forward to establishing the same safety in a clinical study with a more advanced dosing schedule. We believe the schedule used in the trial will also eventually contribute to the efficacy of the therapy“, adds Helsinki University’s Research Professor Akseli Hemminki, co-inventor of CGTG-102 and co-founder of Oncos Therapeutics.
The patient data cumulated over the past 5 years have contributed significantly to the design of the entire clinical development program of the company. “In addition to existing clinical safety data, which is unique to this stage of development, we also have a wealth of supportive data to guide the selection of target tumor types, optimal treatment administration, and other essential elements including clues regarding mechanism of action and possible biomarkers. We are very excited about the design of our entire development program driven by clinical data”, summarizes Chief Medical Officer and Head of Research of Oncos Therapeutics, Mikael von Euler.